Iron overload and tuberculosis: A case for iron chelation therapy

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 1, 2005, Pages 2-9

  Cronje, L ^a   Bornman, Liza ^a  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

Author keywords

Chelation therapy; Iron; Tuberculosis

Indexed keywords

1 AMINO 3 (2 BIPYRIDYL)ISOQUINOLINE DERIVATIVE; 2,3 DIHYDROXYBENZOIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFERRIFERRITHIOCIN; IRON; IRON CHELATING AGENT; ISOQUINOLINE DERIVATIVE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; NORDESFERRITHIOCIN; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; CELL DIVISION; CELL VIABILITY; CHELATION THERAPY; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IRON CHELATION; IRON OVERLOAD; MACROPHAGE FUNCTION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

CHELATING AGENTS; DISEASE PROGRESSION; HUMANS; IRON OVERLOAD; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VIRULENCE;

EID: 11844268093     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Chrichton R R, Wilmet S, Legssyer R, Ward R J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002; 91: 9-18.
2. Lounis N, Truffot-Pernot C, Grosset J, Gordeuk V R, Boelaert J R. Iron and Mycobacterium tuberculosis infection. J Clin Virol 2001; 20: 123-126.
3. Collins H F. The role of iron in infections with intracellular bacteria. Immunol Lett 2003; 85: 193-195.
4. Roitt I, Brostoff J, Male D. In: Immunology. 6th ed. London: Harcourt Publishers Limited; 2001.
5. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002; 32: 70-78.
6. Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002; 29: 471-487.
7. Gordeuk V R. African iron overload. Semin Hematol 2002; 39: 263-269.
8. Mabeza G F, Loyevsky M, Gordeuk V R, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther 1999; 8: 53-75.
9. Di Bisceglie A M, Bonkovsky H L, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-138.
10. Sartori M, Andorno S, Rigamonti C, et al. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001; 33: 157-162.
11. Georgiou N A, van der Bruggen T, Oudshoorn M, Nottet H S L M, Marx J J M, van Asbeck B S. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 2000; 181: 484-490.
12. Schaible U E, Collins H L, Priem F, Kaufmann S H E. Correction of the iron overload defect in β-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 2002; 196: 1507-1513.
13. Moyo V M. Evidence of genetic transmission in African iron overload. Blood 1998; 91: 1076-1082.
14. Savarino A, Pescarmona G P, Boelaert J R. Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 1999; 17: 279-287.
15. Bogdan C, Röllinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000; 12: 64-76.
16. Collins H F, Kaufmann S H, Schaible U E. Iron chelation via deferoxamine exacerbates experimental Salmonellosis via inhibition of the nicotinamine adenine dinucleotide phosphate oxidase-dependent respiratory burst. J Immunol 2002; 168: 3458-3463.
17. Rook G A, Zumla A. Advances in the immunopathogenesis of pulmonary tuberculosis. Curr Opin Pulm Med 2001; 7: 116-123.
18. Polla B S. Therapy by taking away: the case of iron. Biochem Pharmacol 1999; 57: 1345-1349.
19. Jacob A K, Hotchkiss R S, DeMeester S L, et al. Endothelial cell apoptosis is accelerated by inorganic iron and heat via an oxygen radical dependent mechanism. Surgery 1997; 122: 243-254.
20. Jurado R L. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997; 25: 888-895.
21. Ponka P, Lok C N. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31: 1111-1137.
22. Zhong W, Lafuse W P, Zwilling B S. Infection with Mycobacterium avium differentially regulates expression of iron transport protein mRNA in murine peritoneal macrophages. Infect Immun 2001; 69: 6618-6624.
23. Cole S T, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
24. D'Orazio M, Folcarelli S, Mariani F, Colizzi V, Rotilio G, Battistoni A. Lipid modification of the Cu, Zn superoxide dismutase from Mycobacterium tuberculosis. Biochem J 2001; 359: 17-22.
25. Rodriguez G M, Smith I. Mechanisms of iron regulation in mycobacteria: role in physiology and virulence. Mol Microbiol 2003; 47: 1485-1494.
26. De Voss J J, Rutter K, Schroeder B G, Barry C E III. Iron acquisition and metabolism by mycobacteria. J Bacteriol 1999; 181: 4443-4451.
27. De Voss J J, Rutter K, Schroeder B G, Su H, Zhu Y, Barry C E III. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A 2000; 97: 1252-1257.
28. Dussurget O, Smith I. Interdependence of mycobacterial iron regulation, oxidative-stress response and isoniazid resistance. Trends Microbiol 1998; 6: 354-358.
29. Forbes J F, Gros P. Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions. Trends Microbiol 2001; 9: 397-403.
30. Agranoff D D, Krishna S. Metal ion homeostasis and intracellular parasitism. Mol Microbiol 1998; 28: 403-412.
31. Domenech P, Pym A S, Cellier M, Barry III C E, Cole S T. Inactivation of the Mycobacterium tuberculosis Nramp orthologue (mntH) does not affect virulence in a mouse model of tuberculosis. FEMS Microbiol Lett 2002; 207: 81-86.
32. Rodriguez G M, Voskuil M I, Gold B, Schoolnik G K, Smith I. ideR, an essential gene in Mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 2002; 70: 3371-3381.
33. Boechat N, Lagier-Roger B, Petit S, et al. Disruption of the gene homologous to mammalian Nramp1 in Mycobacterium tuberculosis does not affect virulence in mice. Infect Immun 2002; 70: 4214-4231.
34. Pym A S, Domenech P, Honore N, Song J, Deretic V, Cole S T. Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol 2001; 40: 879-889.
35. Master S, Zahrt T C, Song J, Deretic V. Mapping of Mycobacterium tuberculosis katG promoters and their differential expression in infected macrophages. J Bacteriol 2001; 183: 4033-4039.
36. Dubnau E, Smith I. Mycobacterium tuberculosis gene expression in macrophages. Microbes Infect 2003; 5: 629-637.
37. Quadri L E, Sello J, Keating T A, Weinreb P H, Walsh C T. Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulence-conferring siderophore mycobactin. Chem Biol 1998; 5: 631-645.
38. Kasvosve I, Gomo Z A, Mvundura E, et al. Haptoglobin polymorphism and mortality in patients with tuberculosis. Int J Tuberc Lung Dis 2000; 4: 771-775.
39. Aucan C, Walley A J, Greenwoord B M, Hill AVS. Haptoglobin genotypes are not associated with resistance to severe malaria in The Gambia. Trans R Soc Trop Med Hyg 2002; 96: 327-328.
40. Salter-Cid L, Brunmark A, Li Y, et al. Transferrin receptor is negatively modulated by the haemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA 1999; 96: 5434-5439.
41. Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert R J. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis 2003; 7: 575-579.
42. Flynn J L, Goldstein M R, Triebold K J, Koller B, Bloom B R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12013-12017.
43. Gomes M S, Dom G, Pedrosa J, Boelaert J R, Appelberg A. Effects of iron deprivation on Mycobacterium avium growth. Tubercle Lung Dis 1999; 79: 321-328.
44. Gomes M S, Boelaert J R, Appelberg A. Role of iron in experimental Mycobacterium avium infection. J Clin Virol 2001; 20: 117-122.
45. Boelaert J R, Weinberg G A, Weinberg E D. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996; 5: 36-46.
46. Gomes M S, Appelberg R. Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance against Mycobacterium avium. Immunology 1998; 95: 165-168.
47. Douvas G S, May M H, Kolnagou A, Kontoghiorghes G H. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity. Arzneimittelforschung 2002; 52: 45-52.
48. Cabatchik Z I, Moody-Haupt S, Gordeuk V R. Iron chelators as anti-infectives: malaria as paradigm. FEMS Immunol Med Microbiol 1999; 29: 289-298.
49. Kontoghiorghes G J, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23: 211-223.
50. Bremner P, Heinrich M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 2002; 54: 453-472.
51. Pietrangelo A, Borella F, Casalgrandi G, et al. Antioxidant activity of Silybin in vivo during long-term iron overload in rats. Gastroenterology 1995; 109: 1941-1949.
52. Goudeau C, Loyevsky M, Kassim O O, et al. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum. Br J Haematol 2001; 115: 918-923.
53. Hershko C, Konijn A M, Nik H P, Breuer W, Cabantchik Z I, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radio iron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells inculture. Blood 2001; 97: 1115-1122.
54. Hermes-Lima M, Ponka P, Schulman H M. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim Biophys Acta 2000; 1523: 154-160.
55. Link G, Konijn A M, Breuer W, Cabantchik Z I, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labelled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-138.
56. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 1994; 7: 965-1000.
57. Gordeuk V R, McLaren C E, Macphail A P, Deichsel G, Bothwell T H. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachans's 1929 thesis revisited. Blood 1996; 87: 3470-3476.
58. Adams H G, Jordan C. Infections in the alcoholic. Med Clin North Am 1984; 68: 179-200.
59. van Asbeck B S, Georgiou N A, van der Bruggen T, Oudshoorn M, Nottet H S, Marx J J. Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol 2001; 20: 141-147.
60. Botha T, Ryffel B. Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 2002; 107: 350-357.